At MavriX Bio, our mission is to bring life-changing therapies to individuals living with Angelman syndrome (AS).

Backed by the Foundation for Angelman Syndrome Therapeutics (FAST) and managed by the AS²Bio drug development accelerator, we are committed to advancing the first investigational AAV-delivered gene therapy for AS.


We are driven by science, inspired by patients, and focused on delivering transformative solutions where no approved treatments currently exist.